Sino Biopharmaceutical (HK:1177) has released an update.
Sino Biopharmaceutical has announced positive results from their Phase III study of Anlotinib Hydrochloride Capsule in combination with Penpulimab for the treatment of advanced hepatocellular carcinoma, paving the way for a new first-line treatment option. The study met its primary endpoints of progression-free and overall survival, exceeding predefined superiority thresholds. The company plans to submit a marketing application soon, with the potential to provide a new hope for patients with advanced liver cancer.
For further insights into HK:1177 stock, check out TipRanks’ Stock Analysis page.
